Joost Schalkwijk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joost Schalkwijk has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Patrick L. J. M. Zeeuwen
Department of Dermatology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
15 shared publications - Ellen H. van Den Bogaard
Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
8 shared publications - Patrick A. M. Jansen
Department of Dermatology, Radboud Research Institute for Medical Innovation , Radboudumc, Nijmegen
6 shared publications - Diana Rodijk-Olthuis
Department of Dermatology, Radboud University Medical Center Radboud Institute for Molecular Life Sciences (RIMLS) Nijmegen The Netherlands
5 shared publications - Hanna Niehues
Department of Dermatology, Radboudumc, Nijmegen, The Netherlands
5 shared publications - Ivonne M. J. J. van Vlijmen‐Willems
Department of Dermatology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
5 shared publications
Latest Publications
- 22 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (9) , 2013-2028.e2
The Aryl Hydrocarbon Receptor Regulates Epidermal Differentiation through Transient Activation of TFAP2A
- 22 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (9) , 2013-2028.e2
The Aryl Hydrocarbon Receptor Regulates Epidermal Differentiation through Transient Activation of TFAP2A
- Open Access
The aryl hydrocarbon receptor regulates epidermal differentiation through transient activation of TFAP2A
The aryl hydrocarbon receptor (AHR) is an evolutionary conserved environmental sensor identified as indispensable regulator of epithelial homeostasis and barrier organ function. Molecular signaling cascade and target genes upon AHR activation and their contribution to cell and tissue function are however not fully understood. Multi-omics analyses using human skin keratinocytes revealed that, upon ligand activation, AHR binds open chromatin to induce expression of transcription factors (TFs), e.g., Transcription Factor AP-2α (TFAP2A), as a swift response to environmental stimuli. The terminal differentiation program including upregulation of barrier genes, filaggrin and keratins, was mediated by TFAP2A as a secondary response to AHR activation. The role of AHR-TFAP2A axis in controlling keratinocyte terminal differentiation for proper barrier formation was further confirmed using CRISPR/Cas9 in human epidermal equivalents. Overall, the study provides novel insights into the molecular mechanism behind AHR-mediated barrier function and potential novel targets for the treatment of skin barrier diseases.
Open AccessThe aryl hydrocarbon receptor regulates epidermal differentiation through transient activation of TFAP2A
The aryl hydrocarbon receptor (AHR) is an evolutionary conserved environmental sensor identified as indispensable regulator of epithelial homeostasis and barrier organ function. Molecular signaling cascade and target genes upon AHR activation and their contribution to cell and tissue function are however not fully understood. Multi-omics analyses using human skin keratinocytes revealed that, upon ligand activation, AHR binds open chromatin to induce expression of transcription factors (TFs), e.g., Transcription Factor AP-2α (TFAP2A), as a swift response to environmental stimuli. The terminal differentiation program including upregulation of barrier genes, filaggrin and keratins, was mediated by TFAP2A as a secondary response to AHR activation. The role of AHR-TFAP2A axis in controlling keratinocyte terminal differentiation for proper barrier formation was further confirmed using CRISPR/Cas9 in human epidermal equivalents. Overall, the study provides novel insights into the molecular mechanism behind AHR-mediated barrier function and potential novel targets for the treatment of skin barrier diseases.
- Open Access
- 7 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (8) , 1520-1528.e5
Investigations into the FLG Null Phenotype: Showcasing the Methodology for CRISPR/Cas9 Editing of Human Keratinocytes
- 7 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (8) , 1520-1528.e5
Open AccessInvestigations into the FLG Null Phenotype: Showcasing the Methodology for CRISPR/Cas9 Editing of Human Keratinocytes
- Open Access
- 1 July 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (7) , 1947-1955.e6
Antimicrobial Late Cornified Envelope Proteins: The Psoriasis Risk Factor Deletion of LCE3B/C Genes Affects Microbiota Composition
- 1 July 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (7) , 1947-1955.e6
Open AccessAntimicrobial Late Cornified Envelope Proteins: The Psoriasis Risk Factor Deletion of LCE3B/C Genes Affects Microbiota Composition
- Open Access
- 20 April 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
Drug resistance and a dire lack of transmission-blocking antimalarials hamper malaria elimination. Here, we present the pantothenamide MMV693183 as a first-in-class acetyl-CoA synthetase (AcAS) inhibitor to enter preclinical development. Our studies demonstrate attractive drug-like properties and in vivo efficacy in a humanized mouse model of Plasmodium falciparum infection. The compound shows single digit nanomolar in vitro activity against P. falciparum and P. vivax clinical isolates, and potently blocks P. falciparum transmission to Anopheles mosquitoes. Genetic and biochemical studies identify AcAS as the target of the MMV693183-derived antimetabolite, CoA-MMV693183. Pharmacokinetic-pharmacodynamic modelling predict that a single 30 mg oral dose is sufficient to cure a malaria infection in humans. Toxicology studies in rats indicate a > 30-fold safety margin in relation to the predicted human efficacious exposure. In conclusion, MMV693183 represents a promising candidate for further (pre)clinical development with a novel mode of action for treatment of malaria and blocking transmission.
- 20 April 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
Open AccessPreclinical characterization and target validation of the antimalarial pantothenamide MMV693183
Drug resistance and a dire lack of transmission-blocking antimalarials hamper malaria elimination. Here, we present the pantothenamide MMV693183 as a first-in-class acetyl-CoA synthetase (AcAS) inhibitor to enter preclinical development. Our studies demonstrate attractive drug-like properties and in vivo efficacy in a humanized mouse model of Plasmodium falciparum infection. The compound shows single digit nanomolar in vitro activity against P. falciparum and P. vivax clinical isolates, and potently blocks P. falciparum transmission to Anopheles mosquitoes. Genetic and biochemical studies identify AcAS as the target of the MMV693183-derived antimetabolite, CoA-MMV693183. Pharmacokinetic-pharmacodynamic modelling predict that a single 30 mg oral dose is sufficient to cure a malaria infection in humans. Toxicology studies in rats indicate a > 30-fold safety margin in relation to the predicted human efficacious exposure. In conclusion, MMV693183 represents a promising candidate for further (pre)clinical development with a novel mode of action for treatment of malaria and blocking transmission.
- Open Access
- 22 October 2021
- Published by Elsevier in JID Innovations
- Vol. 2 (1) , 100066
Identification of Keratinocyte Mitogens: Implications for Hyperproliferation in Psoriasis and Atopic Dermatitis
- 22 October 2021
- Published by Elsevier in JID Innovations
- Vol. 2 (1) , 100066
Open AccessIdentification of Keratinocyte Mitogens: Implications for Hyperproliferation in Psoriasis and Atopic Dermatitis
- 1 October 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (10) , S168
120 Identification of keratinocyte mitogens: implications for hyperproliferation in psoriasis and atopic dermatitis
- 1 October 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (10) , S168
120 Identification of keratinocyte mitogens: implications for hyperproliferation in psoriasis and atopic dermatitis
- 1 February 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (2) , 415-424.e10
Targeting the Cutaneous Microbiota in Atopic Dermatitis by Coal Tar via AHR-Dependent Induction of Antimicrobial Peptides
- 1 February 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (2) , 415-424.e10
Targeting the Cutaneous Microbiota in Atopic Dermatitis by Coal Tar via AHR-Dependent Induction of Antimicrobial Peptides
- 18 September 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (510)
Antimalarial pantothenamide metabolites target acetyl–coenzyme A biosynthesis in Plasmodium falciparum
Pantothenamides form antimetabolites that interfere with acetyl-CoA metabolism in the human malaria parasite Plasmodium falciparum.
- 18 September 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (510)
Antimalarial pantothenamide metabolites target acetyl–coenzyme A biosynthesis in Plasmodium falciparum
Pantothenamides form antimetabolites that interfere with acetyl-CoA metabolism in the human malaria parasite Plasmodium falciparum.
- Open Access
- 6 June 2019
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 72 (9) , 682-692
Stable pantothenamide bioisosteres: novel antibiotics for Gram-positive bacteria
The emergence of multidrug resistant bacteria has prioritized the development of new antibiotics. N-substituted pantothenamides, analogs of the natural compound pantetheine, were reported to target bacterial coenzyme A biosynthesis, but these compounds have never reached the clinic due to their instability in biological fluids. Plasma-stable pantothenamide analogs could overcome these issues. We first synthesized a number of bioisosteres of the prototypic pantothenamide N7-Pan. A compound with an inverted amide bond (CXP18.6-012) was found to provide plasma-stability with minimal loss of activity compared to the parent compound N7-Pan. Next, we synthesized inverted pantothenamides with a large variety of side chains. Among these we identified a number of novel stable inverted pantothenamides with selective activity against Gram-positive bacteria such as staphylococci and streptococci, at low micromolar concentrations. These data provide future direction for the development of pantothenamides with clinical potential.
- 6 June 2019
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 72 (9) , 682-692
Open AccessStable pantothenamide bioisosteres: novel antibiotics for Gram-positive bacteria
The emergence of multidrug resistant bacteria has prioritized the development of new antibiotics. N-substituted pantothenamides, analogs of the natural compound pantetheine, were reported to target bacterial coenzyme A biosynthesis, but these compounds have never reached the clinic due to their instability in biological fluids. Plasma-stable pantothenamide analogs could overcome these issues. We first synthesized a number of bioisosteres of the prototypic pantothenamide N7-Pan. A compound with an inverted amide bond (CXP18.6-012) was found to provide plasma-stability with minimal loss of activity compared to the parent compound N7-Pan. Next, we synthesized inverted pantothenamides with a large variety of side chains. Among these we identified a number of novel stable inverted pantothenamides with selective activity against Gram-positive bacteria such as staphylococci and streptococci, at low micromolar concentrations. These data provide future direction for the development of pantothenamides with clinical potential.